Abstract
ObjectiveThe patent expiry of a number of biological medicines and the advent of biosimilars raised the expectations of healthcare commissioners that biosimilars would reduce the high cost of these medicines...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have